Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | F7 | P08709 | 3/20 | 0.41 |
| ▸ | F3 | P13726 | 3/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.41 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | FABP3 | P05413 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | GNA15 | P30679 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12216913 | 0.89 | TRPV1 (0.40) | ALDH1A1KDM4EF7F3PPARG | |
| SCHEMBL15800641 | 0.84 | FAAH (0.40) | ALDH1A1DUSP3HPGD | |
| SCHEMBL246601 | 0.84 | TRPV1 (0.36) | ALDH1A1KDM4EF7F3PPARG | |
| SCHEMBL22838309 | 0.84 | TRPV1 (0.36) | ALDH1A1KDM4EF7F3PPARG | |
| SCHEMBL22838284 | 0.83 | TRPV1 (0.36) | ALDH1A1KDM4EF7F3PPARG | |
| SCHEMBL30446077 | 0.82 | FAAH (0.40) | ALDH1A1KDM4EPPARGPPARDPPARA | |
| SCHEMBL22838307 | 0.82 | FAAH (0.37) | — | |
| SCHEMBL19882101 | 0.82 | CNR1 (0.35) | ALDH1A1KDM4EF7F3PPARG | |
| SCHEMBL2332115 | 0.82 | CNR1 (0.35) | ALDH1A1KDM4EF7F3PPARG | |
| SCHEMBL25067336 | 0.81 | FAAH (0.41) | ALDH1A1KDM4EF7F3PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4495237-B1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORP (CA) | 2026-05-13 | — | — | EP | disclosed |
| US-12453776-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2025-10-28 | — | — | US | disclosed |
| EP-4495237-A2 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | Arbutus Biopharma Corporation (CA) | 2025-01-22 | — | — | EP | disclosed |
| US-20240424105-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-12-26 | — | — | US | disclosed |
| EP-4241767-B1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORP (CA) | 2024-10-23 | — | — | EP | disclosed |
| US-12042541-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-23 | — | — | US | disclosed |
| US-20240042039-A1 | LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-02-08 | — | — | US | disclosed |
| EP-4241767-A2 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | Arbutus Biopharma Corporation (CA) | 2023-09-13 | — | — | EP | disclosed |
| US-11712476-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-01 | — | — | US | disclosed |
| US-11712476-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-01 | — | — | US | disclosed |
| US-9139554-B2 | Amino lipids and methods for the delivery of nucleic acids | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2015-09-22 | — | — | US | disclosed |
| US-9139554-B2 | Amino lipids and methods for the delivery of nucleic acids | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2015-09-22 | — | — | US | disclosed |
| EP-2350043-B9 | IMPROVED AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORP (CA) | 2014-08-20 | — | — | EP | disclosed |
| EP-2350043-B1 | IMPROVED AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORP (CA) | 2014-03-26 | — | — | EP | disclosed |
| US-20110311582-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2011-12-22 | — | — | US | disclosed |
| US-20110311582-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2011-12-22 | — | — | US | disclosed |
| US-20110256175-A1 | AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-10-20 | — | — | US | disclosed |
| US-20110256175-A1 | AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-10-20 | — | — | US | disclosed |
| WO-2010054401-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010042877-A1 | IMPROVED AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12453776-B2 | Lipids and compositions for the delivery of therapeutics | PHOSPHO1, MBOAT1, SGMS1 | ALDH1A1 2999/4885KDM4E 1867/4885F7 2967/4885 |
| US-20240424105-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | PHOSPHO1, MBOAT1, SGMS1 | ALDH1A1 3640/4885KDM4E 1963/4885F7 3390/4885 |
| US-12042541-B2 | Lipids and compositions for the delivery of therapeutics | PHOSPHO1, MBOAT1, SGMS1 | ALDH1A1 2999/4885KDM4E 1867/4885F7 2967/4885 |
| US-11712476-B2 | Lipids and compositions for the delivery of therapeutics | SGMS2, APOB, PHOSPHO1 | ALDH1A1 4140/4885KDM4E 1410/4885F7 977/4885 |
| US-20240042039-A1 | LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | PHOSPHO1, MBOAT1, SGMS1 | ALDH1A1 2999/4885KDM4E 1867/4885F7 2967/4885 |
| US-20110311582-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | APOB, LPAR3, LPAR2 | ALDH1A1 4355/4885KDM4E 1001/4885F7 1596/4885 |
| US-20110256175-A1 | AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | NSUN3, SARNP, LDLR | ALDH1A1 4284/4885KDM4E 3120/4885F7 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.